๐ŸŽ Black Friday: up to 50% off of annual plans
Essity AB (publ) (STO:ESSITY.B)
Sweden flag Sweden ยท Delayed Price ยท Currency is SEK
286.50
+1.30 (0.46%)
Nov 20, 2026, 5:29 PM CET
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Health & Medical targets above 3% organic growth and a long-term EBITDA margin of at least 19%; 9M growth was 1.6% and margin was 18.6%. Priorities include North American expansion, targeted M&A and selective pricing, mix and cost actions.

Feng Zhang
Analyst, Jefferies

Hi, everyone. Thanks for joining us today. I am Feng Zhang from Jefferies. I am very pleased to be joined by Essity Head of Health & Medical Business, Anand Chandarana, today. We are going to spend 25 minutes together with 15 minutes in the presentation, and then we will hold a Q&A session. Hi, Anand.

Anand Chandarana
Head of Health and Medical Business, Essity

Hi.

Feng Zhang
Analyst, Jefferies

Welcome.

Anand Chandarana
Head of Health and Medical Business, Essity

Good morning, everyone. Just about, I think. My name is Anand Chandarana. I am going to have the pleasure to talk to you for a couple of minutes about Essity. We are one of the world's biggest hygiene and health companies. As you see on the stage there, or as you see on the screen there, we are present across 150 different markets. We are serving more or less 1 billion people every single day. The company, just with the key financials as you see on the screen, our net sales about EUR 13 billion a year, SEK 138 billion. We have an EBITDA margin of 14%. Operating cash flow very healthy, as you can see there. Healthy balance sheet, or a strong balance sheet, and return on capital employed, again, very strong and something that we are concentrating on going forward.

Our financial targets of our outlook and our ambitions are to grow at over 3% consistently and to have an EBITDA margin across the portfolio and across the group of 15%. We are made up of four business units. I have the pleasure of leading the Health & Medical business unit, which you see on the far left. That represents 20% of sales and around 25% of our profit. Personal Care, which is our feminine, baby, and incontinence retail products, that is 25% of sales. We have our Consumer Tissue business unit, which is 30% of sales. That is toilet tissue, other tissue for the consumer at home. Then we have our Professional Hygiene business, which is our Tork brand, 25% of sales. I was happy to see that the bathrooms here also use Tork, and our customers of ours.

Hopefully you get the chance to experience some of our solutions. That represents 25% of sales, as I say. As I said to you earlier on, Health & Medical is the business unit that I have the pleasure of leading. 20% of sales, 25% of the group's margin, made up of four categories. It is incontinence products, and that is the TENA brand. We have wound care, which is advanced wound care and dressings. We have compression therapy, so that is garments, wraps, and bandages related to phlebology and lymphology conditions. We have our soft orthopedics, which is fracture management, physiotherapy, braces, and supports. These are solutions that are there to help people with aging-related chronic conditions, and that is what brings the portfolio together. Our desire and our ambition is to be the undisputed leader in preventing and treating those conditions that we serve.

Just a split of the business unit of Health & Medical to show you there. The lion's share, 58%, is incontinence products. Then we have 21% of sales coming from wound care, and that is the faster growing of the portfolio. 11% from orthopedics, fracture management, physiotherapy, and 10% from compression therapy. We are largely a European player, but we have bets and ambitions to grow in the U.S. and also in other emerging markets, and you can see that on the bottom right. Our growth rate in 2025 of 1% is not in line with our ambitions. Our ambition is to grow above 3% in Health & Medical, and we are on our way to delivering that in a more consistent manner, as is our ambition to have a stable 19% or above of EBITDA margin. In 2025, we delivered 18.

I will not dwell too much on this other than to say we are operating in a market or a range of categories that has an addressable market of EUR 17 billion, rising at 3%-4%, driven by those aging conditions and increasing chronic conditions, as I mentioned earlier on. In incontinence healthcare, we are the de facto market leader with TENA. You can see that split differently in the different regions, which gives us some upsides in places like North America. In wound care, we are a global number five, but with a stronger position in Europe. Again, that gives us leverage and the ability to have upsides in North America and in the developing and emerging markets. Orthopedics, we are number two, but where it counts, which is the areas that we focus, so fracture management and physiotherapy, we are global number one.

In compression therapy, again, global number one, albeit with other strong players in the space too. We believe that we operate in very attractive market segments, non-cyclical, durable demand, driven by aging populations and the increase in chronic conditions. We have strong positions in the categories in which we operate, which give us embeddedness, you could say stickiness. We have, I would say, and maybe we will discuss this a little bit later, Feng, we have the challenge of being in healthcare systems that are under pressure to deliver more with less, but that also gives us a great opportunity. That means there are needs that are surfacing all the time that gives us the possibility to address those.

Players that address emerging needs in the healthcare space, particularly when it is to help healthcare systems deliver more with less, they will be successful, and that is what we do. Our positions in our categories also create a moat around us and create high barriers to entry for others wanting to play in this space. You need a critical amount of infrastructure. Whether it be in manufacturing, in sales, in market access, in order to operate in our categories, we have that, which gives us the ability to leverage operationally. I will try to skip through this very quickly, but I am sure all of you know, when you are operating in the healthcare space, you have to simultaneously satisfy multiple stakeholders at the same time.

We are operating across different channels. We are working and partnering with healthcare systems and providers, hospital systems, governments sometimes, and also hospital and IDNs, of course, across different geographies. We are supporting and liaising directly with professional caregivers, nurses, doctors, et cetera, but increasingly family caregivers, especially with the burden of aging populations hitting not only healthcare, but also in the home. We work directly with and serve patients and consumers directly through e-commerce and other channels. Those channel partners, whether it be pharmacists, distributors, et cetera, are a key part of the value chain that we also interface with and partner with. Even though we have the four categories, our growth levers, the ones that we concentrate on, are continence care, where we want to go from operating in the treatment of incontinence with absorbent products, et cetera.

We want to go to prevent and reduce, so we are looking at expanded solutions to cover the full spectrum of the continuum of care. In wound care, we have an explicit desire to focus on advanced wound care, and within that, infection management and complication reduction. We believe that we have the right technologies and also the customers have needs that are underserved. We want to leverage strength in the medical part of compression for lifelong conditions. So we are over-indexed our investment in lymphology and medical lifelong compression. These are our growth levers that we focus disproportionately on over the coming period. As you would expect, our M&A ambitions match our growth ambitions, although not necessarily reliant on one another. We would believe that M&A would be an opportunity for us to accelerate and catalyze our focus areas.

In continence care, we would look to add adjacencies in reducing and preventing incontinence, so solutions that support that. In wound care, we would like to add scale in certain geographies, but also double down on advanced wound care, specifically infection and complication reduction. In compression, we are looking at adjacent technologies, particularly with regards to lymphatic conditions, when you have swollen legs, which is a condition that also has a tailwind as a result of increasing obesity, but also, positively, cancer survivors who tend to develop these conditions. So, we have the opportunity to expand our portfolio and our value proposition there. I think I have probably explained to you why we win across different stakeholders, but we have solutions that are well-embedded. We have solutions that come with proven evidence, of course, and we are on the market with trusted brands, trusted positions, and full product-to-service offering.

Our products are also easy to use and well-adopted, which is, of course, a key driver within healthcare, to have the adoption as well as just the market access. Maybe I will pause there, and we can continue our dialogue from so I can move.

Feng Zhang
Analyst, Jefferies

Yeah. That would be great. Thank you. You mentioned, I think you joined since 2020 in Health & Medical side of the business and lead the business for a year. What do you see has been the biggest challenge to deliver profitable growth, and where do you see the biggest opportunity from here?

Anand Chandarana
Head of Health and Medical Business, Essity

Yeah. At the risk of repeating myself, I would say, first of all, it has been a very eventful time since 2020. I joined just before the pandemic, and of course, we had COVID. Then we had the inflationary crisis that followed after that. As a result, we've had to put real focus on profitability, and we've shown that we're a resilient business. You can see that we've restored margins and, in certain cases, also gone further than where we were before. You ask what are the opportunities and the challenges right now. Actually, I think it's two sides of the same coin. The challenge is that healthcare systems are increasingly under pressure. We see capital, of course, and I think you guys see this more than me, capital is going from publicly funded healthcare systems. Governments are putting that increasingly in defense.

At the same time, there is the pressures of aging populations, which create more of a burden on healthcare systems. Meeting that when we have differentiated solutions more at the premium end of the market is, of course, one of the challenges. The way we counter that is, of course, by having evidence, meaningful differentiation, but also helping healthcare systems deliver care efficiency rather than just lower-priced products. As many of you know, healthcare systems typically spend 10%-15% of any given treatment on the products, and the rest is on care delivery. That's where we help those healthcare systems tackle the challenges. I would say that's not only the challenge, but it's also the opportunity.

If you can have solutions which are proven, which release efficiency in care delivery, then you can be successful, and we are starting to see really good signs of that.

Feng Zhang
Analyst, Jefferies

You mentioned about the challenges in the medical sector in general at current environment, and the nine months organic growth is 1.6%.

Anand Chandarana
Head of Health and Medical Business, Essity

Yes.

Feng Zhang
Analyst, Jefferies

That is short of the 3%-4% of the ambition layout in the CMD. So whatever you see that has been dragging, then how to close the growth gap?

Anand Chandarana
Head of Health and Medical Business, Essity

Yeah. I mean, first of all, I am not happy with the 1.6%. That is not something that we are going to stick with, and that is certainly not where we are going to be satisfied. However, it is a turbulent time right now, and we see healthcare systems, of course, under more pressure than ever. So we have had a soft period, I would say, this first nine months. Long-term attractiveness of the categories that we are in, incontinence care, wound care, compression therapy, orthopedics is very, very strong. So the challenge for us is, of course, to capture that demand, and that will be done through strong execution, but also by making sure we have the solutions that resonate with the healthcare systems, offering that care delivery efficiency, as I described. So I would say that is where our obstacles have been.

We want to make sure that healthcare systems are not choosing the cheapest products. Also, tender timing can be a challenge for us as well. In incontinence healthcare, the contract lengths are somewhere sort of four, five years. So we have the possibility over the coming strategic period to choose and ensure that we're best positioned to win those volumes.

Feng Zhang
Analyst, Jefferies

Right. You mentioned tenders, timing. Just in terms of dynamic of volume and price mix.

Anand Chandarana
Head of Health and Medical Business, Essity

Yeah.

Feng Zhang
Analyst, Jefferies

When you think this business mostly driven by tender and the contracts, in terms of winning more tenders to grow volume compares to driving the price mix within the business, which part is more controllable, or which one is the growth, the bigger driver in that sense?

Anand Chandarana
Head of Health and Medical Business, Essity

Yeah. It's a good question. I would put it like this. Three elements to this. The first is that the aging populations and increasing chronic conditions, that drives demand. Execution captures the demand. That's in our control, right? Commercial execution, if that's done correctly, you capture the demand. The quality of the growth is depending on the mix. One of the key elements of our strategy and our execution is ensuring that we push or we concentrate resources in the areas where we have the highest right to win, but also the highest margins. I would say that the demographics drive the growth, execution captures the growth, and mix ensures that the profitability. Sorry. The mix ensures that the quality of growth is the right one.

Feng Zhang
Analyst, Jefferies

Right. You highlighted M&A as the growth driver.

Anand Chandarana
Head of Health and Medical Business, Essity

Yeah.

Feng Zhang
Analyst, Jefferies

How much growth do you expect the M&A contribute within the 3%-4% of growth? In terms of where specific area you're looking for in terms of doing more deals?

Anand Chandarana
Head of Health and Medical Business, Essity

Well, the good news is, or maybe depending on which side of the fence you sit, the 3%-4% is organic growth. That is not factoring in M&A. We would want to do M&A on top. We will do M&A only where it is strategic and where we believe there are synergies and it creates value. The areas that we would like to do M&A in are wound care, specifically advanced wound care. We see the opportunity to have a stronger presence in the growing markets or the markets where we have less of a presence, namely North America or also developing and emerging markets. The second area where we would do M&A is continence care.

We have a very strong position in incontinence products, but when it comes to reducing or preventing incontinence, those are solutions that we would look to buy in to strengthen our overall value proposition. Not only drives the core business, but it also gives us access to new segments. The third one would be for looking at solutions that are adjacent to lymphology. We have compression garments, the best in the industry, very well accepted by clinicians and patients. But of course, either side of that, there are other modes of action and other technologies that would help us. But it is not in the 3%-4%, so M&A is on top. We will do it in a very disciplined way, where we believe that there is a strategic overlap and where there is significant value creation upside.

Feng Zhang
Analyst, Jefferies

Thank you. You mentioned North America in core business. We know that North America is fast-growing area of the business, but it is only 17% of the division.

Anand Chandarana
Head of Health and Medical Business, Essity

Yeah.

Feng Zhang
Analyst, Jefferies

In terms of the market share, you are currently number three in the market. Compares to number one in Europe and Latin America. Is that closing the share gap the priority or?

Anand Chandarana
Head of Health and Medical Business, Essity

It is one of the priorities, absolutely, Feng. Now it sounds like I am giving you a list of things that I am not happy with. I am also not happy with the 17% contribution from North America. It should be much higher. So we have much bigger ambitions in North America. But it is a tale of two halves, if you could put it like that. In Canada, we have a very strong incontinence business. We are the market leader there. Very strong positions, very healthy business. There, the opportunity is for the medical categories, so for wound care, orthopedics, compression, and we are allocating resources there accordingly. On U.S., we have, to your point, a number three position with incontinence care, so a significant upside.

So we are now really double-clicking to see what is the opportunity, what is the full potential of that market space when it comes to incontinence. We have a very strong base upon which to build. We could also do M&A there, but I would expect that within the coming medium term, it would be absolutely a bigger contribution than the 17% from North America.

Feng Zhang
Analyst, Jefferies

That's great. I got questions in terms of margins, actually.

Anand Chandarana
Head of Health and Medical Business, Essity

Yeah.

Feng Zhang
Analyst, Jefferies

It's currently year- to- date is 18.6% of margins. That's also short of the 19% margin in the CMD. Just in terms of getting there, what area you think going to improve? Is it growing mix, driving the mix, growing faster, or is it there's implicit cost savings in there?

Anand Chandarana
Head of Health and Medical Business, Essity

Yeah. It's everything. Maybe I'll start in a different way. 18.6% for the first nine months of this year. I think that shows our resilience and our ability in the business not only to manage our costs, but also manage price. We've said in our quarter three reporting that we expect the cost headwinds to intensify over the coming couple of quarters, coming 12 months. I would be reluctant to presume that it's going to be every single quarter that we'll deliver 18.6% or 19%. Our longer-term aim is to deliver the 19%, and the way we'll do that is different in the short and medium term. In the short term, we will recover selectively with price. We have the possibility to do that, particularly in incontinence, where you have a bigger effect of input costs.

Over the medium term, it's via mix, and it's also via looking at our cost. That cost can be more holistic, right? It's all parts of the value chain, whether it's in value engineering to ensure that the products we deliver to the healthcare systems and the healthcare professionals and the consumers is what they're willing to pay for. It's also in our cost to serve. We see increasingly the opportunity to improve productivity and to get more operating leverage out of our commercial engine, which is, of course, a big cost for many healthcare companies.

Feng Zhang
Analyst, Jefferies

That's very helpful. Just going back to the contract win and tender part of the. What do you see the challenges? You mentioned the four to five years in terms of the time. In terms of winning new contracts. What is the challenge and then what is the dynamic?

Anand Chandarana
Head of Health and Medical Business, Essity

I think the way to win tenders, you have to start preparing for the next contract after the previous contract was won. Let's say today we win a contract, you already need to start thinking four years ahead, and you need to start shaping the contract with the customers, whether you've won it or lost it. That is by ensuring that the healthcare system, the customer, understands what they should be asking for in the upcoming specification. That requires a lot of shaping of standards of care. It requires a lot of close cooperation. It requires showing health economics and evidence. That's what we do. Then leading up to the contract, of course, you have to have the competence, the capability in the organization to execute when the specification is released and when the tender is live.

Then, of course, winning a tender is only the first part of the journey. Then you need to have the ability, the muscles, the competence, the closeness of relationship with the customer. You also need to have the infrastructure in order to turn that into clinical demand, so you drive adoption. I would say throughout a contract period, you have to do different things. We're particularly good at tenders because it's a big part of our business. It's a strength of ours, and we try to leverage that across categories. We're particularly good at market shaping because we're trustworthy, we have the right evidence, and also we have the right relationships. Sometimes those transcend the clinical healthcare layer. You have to often go up to the C-suite. You're often also affecting and influencing governments and healthcare system commissioners.

We do that quite well, particularly here in the U.K., and you would have seen over the last- Well, if you're that way nerdy like I am, you will have seen that there's been a reform in procurement for the NHS, and we've been part of that discussion, but also ensuring that that is translated into how incontinence products are, for example, bought. We start to see the cogs really turning in the right direction. We see that healthcare systems are not only looking at price per piece, they're looking at overall efficiencies, outcomes, where, of course, the biggest gains are to be made. That's what we need to do, and that's where we work quite well on. Not to mention the other things, which is about adoption and execution.

Feng Zhang
Analyst, Jefferies

That's very insightful. But in terms of the pricing cycle within this process, you mentioned because of the length of the contract, is the pricing quite fixed at the beginning, and then you provide adjacent services that where you increase the prices opportunity, or it is more about within the contract that you can do multiple different pricings?

Anand Chandarana
Head of Health and Medical Business, Essity

It is both. We learned our lessons in COVID times. Since then, we have increasingly tried to build in inflation-related clauses into contracts so that there is the ability intra contract to go back and discuss. It is very transparent in that time. Of course, you go back to the customer and say, look, we have got this inflation-related clause. Let us take a look at the costs. These are the indexes or the indices, and this is why we need to drive through a could be, the word eludes me now, but it could be price increases, or it could be subsidies, and it could be those kind of situations. Of course, we take the cycle perspective too.

Leading up to a contract, we look at the cost inputs, we try to foresee what will happen over the contract period, and then we take some bets. Having our scale is also unique, so that helps.

Feng Zhang
Analyst, Jefferies

Right. Thank you very much. Conscious of time, I think it is a good place to leave there.

Anand Chandarana
Head of Health and Medical Business, Essity

Thank you.

Feng Zhang
Analyst, Jefferies

Thanks again for joining us today. It's been very insightful.

Anand Chandarana
Head of Health and Medical Business, Essity

It's a pleasure.

Feng Zhang
Analyst, Jefferies

Thanks for everyone joining us.

Anand Chandarana
Head of Health and Medical Business, Essity

Thank you.